DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–N–0217]

Science Advisory Board to the National Center for Toxicological Research Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Science Advisory Board to the National Center for Toxicological Research. The general function of the committee is to provide advice and recommendations to the Agency on research being conducted at the National Center for Toxicological Research (NCTR). At least one portion of the meeting will be closed to the public.

DATES: The meeting will be held on April 4, 2023, from 9 a.m. to 6:55 p.m. Eastern Time and April 5, 2023, from 9 a.m. to 12:30 p.m. Eastern Time.

ADDRESSES: Please note that due to the impact of this COVID–19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: *https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.* The meeting will be webcast both days and will be available at the following link. *https://fda.zoomgov.com/j/1608491479?pwd=cStKYmZUdDB5RjR1YWZCTW1kcDY2dz09.* Passcode: v0W1q#.

FOR FURTHER INFORMATION CONTACT: Donna Mendrick, National Center for Toxicological Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993–0002, 301–796–8892, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the **Federal Register** about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's website at *https://www.fda.gov/AdvisoryCommittees/default.htm* and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

SUPPLEMENTARY INFORMATON:

Agenda: On April 4, 2023, the Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board will be presented with an overview of the Science Advisory Board Subcommittee Site Visit Report and a response to this review. The Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Food Safety and Applied Nutrition, Center for Tobacco Products, and the Office of Regulatory Affairs will each briefly discuss their specific research strategic needs and potential areas of collaboration.

On April 5, 2023, there will be updates from the NCTR Research Divisions and a public comment session. Following an open discussion of all the information presented, the open session of the meeting will close so the Science Advisory Board members can discuss personnel issues at NCTR.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material is available at *https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm.* Scroll down to the appropriate advisory committee meeting link.

Procedure: On April 4, 2023, from 9 a.m. to 6:55 p.m. Eastern Time and April 5, 2023, from 9 a.m. to 12:30 p.m. Eastern Time, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before March 28, 2023. Oral presentations from the public will be scheduled between approximately 2 p.m. to 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before March 20, 2023. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 21, 2023.

Closed Committee Deliberations: On April 5, 2023, from 2 p.m. to 3 p.m. Eastern Time, the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals associated with the research programs at NCTR.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Donna Mendrick at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at *https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm* for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2023–02095 Filed 1–31–23; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: OS–0990–0476]

Agency Information Collection Request; 30-Day Public Comment Request

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.

DATES: Comments on the ICR must be received on or before March 3, 2023.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain*. Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

FOR FURTHER INFORMATION CONTACT: Sherrette Funn, *Sherrette.Funn@hhs.gov* or (202) 264–0041, or *PRA@HHS.GOV*. When submitting comments or requesting information, please include the document identifier 0990–0476–30D and project title for reference.

SUPPLEMENTARY INFORMATION: Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Title of the Collection: ASPA COVID–19 Public Education Campaign Market Research.

Type of Collection: Revision.

OMB No. 0990–0476.

Abstract:

The Department of Health and Human Services, Office of the Assistant Secretary for Public Affairs. This submission contains five parts: 1. COVID–19 Current Events Tracker; 2. Foundational Focus Groups/Interviews/Dyads; 3. Copy Testing Surveys; 4. Message Matrix Surveys; and 5. Creative Testing Surveys and Experiments. The original package included items 1–3. We are submitting this revision to add items 4 (Message Matrix Surveys) and 5 (Creative Testing Surveys and Experiments) to this collection. All data collection will be from individuals.

Current Events Tracker: The primary purpose of the COVID–19 Current Events Tracker (CET) survey is to continuously track key metrics of importance to the Campaign, including vaccine confidence, familiarity with and trust in HHS, and the impact of external events on key attitudes and behaviors among U.S. adults. The CET involves weekly data collection over 3 years.

Foundational Focus Groups, Interviews, and/or Dyads: The primary purpose is to collect information to inform the Campaign about audience risk knowledge, perceptions, current behaviors, and barriers and motivators to healthy behaviors (including COVID–19 vaccination), to inform the development of Campaign messages and strategy. Over 3 years, we will conduct up to 20 rounds of data collection.

Copy Testing Surveys: Prior to placing Campaign advertisements in market, ASPA will conduct copy testing surveys to ensure the final Campaign messages have the intended effect on target attitudes and behaviors. The copy testing survey will field for a maximum of 36 waves over 3 years.

Message Matrix Surveys: The purpose of the Messaging Matrix surveys is to evaluate, validate, and prioritize Campaign messages for various target audiences. Findings from these surveys will be used to inform the development of Campaign messages and strategy. ASPA will conduct up to 9 Messaging Matrix survey under this package.

Creative Testing Surveys and Experiments: The purpose of the Creative Testing Surveys and Experiments is to assess participant reactions to various Campaign materials to inform the selection and development of creative concepts, messages, or material format used for campaign outreach to key audiences. ASPA will conduct up to 6 waves of data collection under this package.

Estimated Annualized Burden Table

Current Events Tracker

For the CET we estimate that 1,000 complete respondents × 0.12 hours per complete survey submission = approximately 120 burden hours associated with completing this survey each wave. No separate screening of participants will be required because Ipsos stores panel variables that determine the eligibility of each panel member without the need for a screener instrument. Only eligible panel members will be invited to take the survey. Over 138 total waves, the total burden is estimated to be approximately 16,560 total burden hours.

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
Survey Completes: Adults 18+	1,000	1	0.12	120
Total, all Waves (138)	138,000	1	0.12	16,560

Foundational Focus Groups, Interviews, and/or Dyads

For the foundational focus groups, we estimate screening a maximum of 2,500 potential respondents × .09 hours (5 minutes) = 225 hours associated with screening participants during each round. In addition, each round will include a maximum of 108 respondents × 1.5 hours per focus group = 162 burden hours associated with the discussion for each round of focus groups. (Note that the exact burden hours will vary depending on the type of study conducted; these estimates serve as a maximum number of participants/hours because in-depth interviews or dyads would involve fewer participants). Over the course of the Campaign, this will amount to a maximum of 20 rounds of qualitative research, for a total of 7,740 burden hours.

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
FG Screening: Individuals in the reference audience	1,250	1	0.09	112.5

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
FG Screening: Individuals in priority populations	1,250	1	0.09	112.5
FG Participants: Individuals in the reference audience	54	1	1.5	81
FG Participants: Individuals in priority populations	54	1	1.5	81
Total, per round	2,500	1	.155	387.5
Total, all rounds (20)	50,000	1	.155	7,750

Focus group participants are also included in the focus group screening, so are only counted once toward the total number of respondents.
.1548 is approximately 9.3 minutes; it is the weighted average over the screener and interview for all participants.

Copy Testing Surveys

For the copy testing survey, we estimate screening 15,000 potential respondents × .03 hours (2 minutes) = 450 hours associated with screening survey participants during each wave. Note that this is a maximum estimate that may be necessary to find members of particularly small audiences of interest. In addition, we will obtain 1,500 respondents × .33 hours (20 minutes) per submission = 495 hours associated with completed surveys in each wave of Campaign message testing. Over the course of the Campaign, this will amount to a maximum of 36 Waves, for a total of 34,020 burden hours.

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
Survey Screener	15,000	1	0.03	450
Survey Completes	1,500	1	0.33	495
Total, one Wave	15,000	1	0.063	945
Total, all Waves (36)	540,000	1	0.063	34,020

Survey completes are also included in the survey screener, so are only counted once toward the total number of respondents.
.063 is approximately 3.8 minutes; it is the weighted average over the screener and survey for all participants.

Message Matrices

Each Message Matrix survey will recruit up to 4,000 respondents. We estimate screening 42,000 potential respondents × 0.03 hours (2 minutes) = 1,400 hours associated with screening survey participants. Note that this is a maximum estimate that may be necessary to find members of particularly small audiences of interest. In addition, we will obtain survey responses from up to 4,000 respondents: 4,000 × 0.33 hours (20 minutes) = 1,333 hours associated with survey completion. Over the course of the Campaign, this will amount to a maximum of 9 rounds of data collection, for a total of 24,600 burden hours.

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
Survey Screener	42,000	1	0.03	1,400
Survey Completes: Adults 18+	4,000	1	0.33	1,333
Total, per round	42,000	1	0.065	2,733
Total, all rounds (9)	378,000	1	0.065	24,600

Survey completes are also included in the survey screener, so are only counted once toward the total number of respondents.
.065 is approximately 3.9 minutes; it is the weighted average over the screener and survey for all participants.

Creative Testing Surveys and Experiments

Each Creative Testing Survey or Experiment will recruit up to 3,000 respondents. We estimate screening 42,000 potential respondents × 0.03 hours (2 minutes) = 1,400 hours associated with screening survey participants. Note that this is a maximum estimate that may be necessary to find members of particularly small audiences of interest. In addition, we will obtain survey responses from up to 3,000 respondents: 3,000 × 0.33 hours (20 minutes) = 1,000 hours associated with survey completion. Over the course of the Campaign, this will amount to a maximum of 6 rounds of data collection, for a total of 14,400 burden hours.

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
Survey Screener	42,000	1	0.03	1,400
Survey Completes: Adults 18+	3,000	1	0.33	1,000
Total, per round	42,000	1	0.057	2,400
Total, all rounds (6)	252,000	1	0.057	14,400

Survey completes are also included in the survey screener, so are only counted once toward the total number of respondents.
.057 is approximately 3.4 minutes; it is the weighted average over the screener and survey for all participants.

Sum of All Studies

Total Respondents: 1,358,000.

Total Burden Hours: 97,330.

Sherrette A. Funn,

Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.

[FR Doc. 2023–02108 Filed 1–31–23; 8:45 am]

BILLING CODE 4150–25–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting of the Pediatrics Study Section.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Pediatrics Study Section.

Date: March 9, 2023.

Closed: 11:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Eunice Kennedy Shriver National Institute, of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2137B, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Joanna Kubler-Kielb, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, 301–435–6916, *kielbj@mail.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: *https://www.nichd.nih.gov/about/org/der/srb,* where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS)

Dated: January 26, 2023.

David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–02063 Filed 1–31–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Maximizing Investigators' Research Award A Study Section.

Date: February 27–28, 2023.

Time: 8:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesdan Hotel, Tapestry Collection by Hilton, 8120 Wisconsin Ave, Bethesda, MD 20814.

Contact Person: Mollie Kim Manier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–0510, *mollie.manier@nih.gov.*

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Neurological, Mental and Behavioral Health Study Section.

Date: February 27–28, 2023.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Ave. NW, Washington, DC 20037.

Contact Person: Allison Kurti, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1007J, Bethesda, MD 20892, (301) 594–1814, *kurtian@csr.nih.gov.*

Name of Committee: Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group; Imaging Technology Development Study Section.

Date: February 27–28, 2023.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Guo Feng Xu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, (301) 237–9870, *xuguofen@csr.nih.gov.*

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Health Promotion in Communities Study Section.

Date: February 27–28, 2023.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Aubrey Spriggs Madkour, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000C, Bethesda, MD 20892, (301) 594–6891, *madkouras@csr.nih.gov.*